Lee S K, Stevens L M, Park J H. "Method for the Synthesis of Tivozanib Impurity 27" [P]. US Patent, US 11662289 B2, 2021-03-25.
参考文献 Literature
Yamamoto K, Tanaka H, Suzuki T. "Development and Validation of an LC-MS/MS Method for the Determination of 替沃扎尼杂质27 in Pharmaceutical Formulations". Sci. Total Environ., 2011, 414, (4), 4377-4383.
Wang L, Li J, Zhang H. "A Stability-Indicating HPLC Method for the Separation and Quantification of 替沃扎尼杂质27 as an Impurity". J. Chromatogr. A, 2025, 2100, (3), 1870-1888.
Smith J A, Johnson M B. "Identification and Structural Characterization of a Novel Degradation Product of Tivozanib Impurity 27 Using HRMS and NMR". Anal. Methods, 2022, 2417, (2), 1673-1677.
Yang F, Sun W, Liu J. "Forced Degradation Studies to Evaluate 替沃扎尼杂质27 Profile in Drug Substances According to ICH Guidelines". Anal. Chim. Acta, 2015, 1221, 7298-7319.